Tempus AI, Inc. company profile

Overview

Tempus AI, Inc. is a healthcare technology and precision-medicine company that combines diagnostic testing with clinical and molecular data, analytics and artificial intelligence. Its platform is designed to support personalized, data-informed patient care and help life-sciences companies develop therapies. The company’s two principal product lines are Diagnostics, including oncology and hereditary testing, and Data and applications, which includes data products, clinical tools and AI-enabled applications. Tempus says its mission is to make diagnostics more intelligent and improve patient care through AI and data-driven decisions.[1]

Tempus primarily operates in the United States, with a network spanning more than 5,000 healthcare-institution sites; a joint venture also extends its activities into Japan. It reported 3,800 full-time employees as of December 31, 2025, and FY2025 revenue of $1.271 billion. Its platform launched in 2016.[4] [1]

Products & services

Tempus’s oncology diagnostics include tissue-based **xT** and **xR** profiling, liquid-biopsy **xF**, whole-exome **xE**, hereditary-risk **xG**, and residual-disease monitoring **xM**. The **xT** assay profiles 648 genes at approximately 500× coverage, can incorporate matched-normal saliva or blood, and assesses biomarkers including tumor mutational burden, microsatellite instability, and gene fusions; the company reports an approximately 10-day turnaround. **xR** provides full-transcriptome profiling at 50 million paired-end reads, including detection of fusions in more than 100 targeted genes. **xF** is a 105-gene liquid-biopsy assay, while **xE** assesses the tumor exome for actionable variants and neoantigens.[10][11]

The **xM** assay is described as a tumor-naïve plasma test using variant and methylation workflows to monitor residual disease. The company also offers hereditary cancer testing, including the xG and xG+ panels described in its filings; its current hereditary testing page lists Ambry Genetics panels CancerNext-Expanded, CancerNext, and BRCAplus, with optional RNA analysis.[11][12] Its other clinical products include **Next**, which uses machine learning to identify potential care gaps, and **ECG-AI**, which analyzes resting 12-lead ECGs to identify patients at elevated risk of atrial fibrillation; the ECG-AI tool is not described as a stand-alone AF diagnosis.[13]

For life-sciences customers, **Insights** provides de-identified clinical and molecular data, analytics, and organoid modeling and screening services. **Trials** uses AI and near-real-time clinical data to identify potential clinical-trial matches and can support site activation and enrollment. Tempus also offers **Algos**, algorithmic diagnostic products, and a data platform that structures and harmonizes clinical, molecular, and imaging information for research and care applications.[16] In the first half of 2026, Diagnostics revenue was $550.4 million, up 26.4% year over year, and Data and applications revenue was $180.2 million, up 33.7%; the filings report these as business-line results rather than individual product revenue.[19] [10]

Geographic presence

Tempus AI’s geographic footprint is concentrated in the United States. Its diagnostic testing laboratories are located in Chicago, Atlanta, Raleigh, Aliso Viejo, and Minneapolis, and nearly all diagnostic revenue comes from tests performed at those U.S. labs. The company describes its life-sciences sequencing services as reaching more than 50 countries, but does not disclose revenue by country or region.[20]

The company’s principal executive office is in Chicago, where it also leases laboratory and office space. Its other disclosed facilities include leased space in Atlanta, Raleigh, and Minneapolis, an owned lab and land in Aliso Viejo, and offices in New York and Redwood City. As of December 31, 2025, Tempus had more than 3,800 employees, including 1,163 in Chicago, 264 in Orange County, California, and 130 in Raleigh; the filing does not provide a complete geographic employee breakdown.[23]

Tempus also has a 50/50 joint venture with SoftBank, SB Tempus Corp., for clinical sequencing, patient-data organization, and real-world-data activities in Japan; no Japan revenue is quantified in the filing.[26] [20]

Business segments

Tempus AI reports one operating and reportable segment; its chief operating decision maker reviews results and allocates resources on a consolidated basis. The company also presents revenue by business line, but these are not separate reportable segments.[27][28]

Its two business lines are **Diagnostics**, including oncology and hereditary testing, next-generation sequencing diagnostics, PCR profiling, and other pathology testing; and **Data and applications**, including Insights, Next, Trials, and Algos. Insights provides life-sciences customers with de-identified linked clinical, molecular, and imaging data and analytics tools, while Trials helps pharmaceutical companies reach patients for clinical trials.[6]

For full-year 2025, Tempus gave preliminary, unaudited revenue of approximately $1.27 billion: Diagnostics contributed about $955 million (approximately 75%) and Data and applications about $316 million (approximately 25%). The 2025 10-K reports audited Diagnostics revenue of $955.4 million; these business-line figures should not be treated as formal segment revenue.[33] For the six months ended June 30, 2026, revenue was $550.4 million from Diagnostics (75.3%) and $180.2 million from Data and applications (24.7%), out of $730.6 million total.[38] [27]

Company history

Tempus was founded by Eric Lefkofsky in 2015 as Bioin, Inc.; it adopted the Tempus name that year, became Tempus Labs in 2016, and was renamed Tempus AI in 2023.[23] In 2016, Dr. Kevin White joined as president to oversee scientific operations.[39]

The company began expanding its clinical testing and data capabilities in 2017, launching the xT cancer sequencing panel and Tempus O, a platform for structuring and annotating clinical data. In 2018, it added whole-exome sequencing and liquid-biopsy testing and began its first full year of laboratory operations.[40]

Tempus expanded through acquisitions and new offerings, including genomics laboratory AKESOgen (announced in 2019), cardiology technology company Mpirik (2023), and the standalone RNA sequencing test xR (2023).[45] It went public in June 2024, completed its acquisition of genetic testing company Ambry Genetics in February 2025, and completed its acquisition of digital pathology AI company Paige in August 2025.[48] In 2026, Tempus announced an agreement to acquire Personalis; the cited filing describes an agreement, not a completed acquisition.[51] [23]

Continue your research

From company context to financial detail.

Explore original sources and worldwide fundamental financial data and intelligence with Finbar.

Explore Tempus AI, Inc. in Finbar ↗

Tempus AI, Inc.